Besides massive body weight loss, laparoscopic sleeve gastrectomy (LSG) causes massive lean mass, including fat-free mass (FFM) and skeletal muscle mass (SM) that present higher metabolic rates in males. This study examines sex differences in FFM and SM changes of type 2 diabetes (T2D) remission at 12 months post-LSG. This cohort study recruited 119 patients (53.7% females) with T2D and obesity (body mass index 42.2 ± 7.0 kg/m2) who underwent LSG. Fat-mass (FM) loss was higher in males than in females (−12.8 ± 6.2% vs. −9.9 ± 5.0%, p = 0.02) after one-year post-operation. Regardless of the weight-loss difference, males had higher FFM and SM gain than did females (12.8 ± 8.0 vs. 9.9 ± 5.0% p = 0.02 and 6.5 ± 4.3% vs. 4.9 ± 6.2%, p = 0.03, respectively). Positive correlations of triglyceride reduction with FM loss (r = 0.47, p = 0.01) and SM gain (r = 0.44, p = 0.02) over 12 months post-operation were observed in males who achieved T2D remission. The T2D remission rate significantly increased 16% and 26% for each additional percentage of FFM and SM gain one year after LSG, which only happened in males. Increased FFM and SM were remarkably associated with T2D remission in males, but evidence lacks for females.
36 Background: The optimal palliative treatment for gastric outlet obstruction (GOO) remains inconclusive between gastrojejunostomy (G), endoscopic ultrasound-guided gastroenterostomy (E), stomach partitioning gastrojejunostomy (P), endoscopic stenting (S). This study was part of a comprehensive systematic review investigating the outcomes of the aforementioned treatments for malignant GOO. Methods: We conducted a systematic screening randomized controlled trials (RCTs) and cohort studies that compared at least two palliative procedures for GOO from Pubmed, Embase, Cochrane, Web of Science, Scopus, Clinicaltrial, WHO International Clinical Trials Registry Platform. We included full-text studies that reported at least clinical outcomes (clinical success rate, complication rate, 30-day mortality rate, and reintervention rate). We conducted this network meta-analysis using the frequentist approach, inverse variance model with a naïve combination of the treatment effects from RCTs and non-RCTs. We used P-score for treatment ranking. Certainty of evidence was evaluated following CINeMA approach. Results: This study included four RCTs and four prospective and 32 retrospective cohorts with 3417 patients. The pooled overall rates of clinical success, complication, 30-day mortality, and reintervention were 88.9% (95%CI 85.6-91.6), 20.7% (95%CI 17.2-24.7), 5.4% (95%CI 3.2-8.9), and 13.9% (95%CI 10.7-17.9), respectively. P was ranked the safest for reintervention rate (P-score: 0.90) due to obstruction and complication post-procedure (P-score: 0.88 and 0.81, respectively). E was ranked the safest for the 30-day mortality rate (P-score: 0.82). Cluster rank combined the P-score for 30-day mortality and reintervention or reintervention rate due to obstruction showed the benefit of P and E versus G and S (cophenetic correlation coefficient - c: 0.94 and 0.94, respectively). Cluster rank combined with the P-score for 30-day mortality and reintervention due to complication showed the benefit of P (c:0.99). The overall certainty of evidence was low to very low. Conclusions: P and E are recommended for malignant GOO, and P should be the first choice in centers with limited resources or cases of unfeasible or unsuccessful E.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.